Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease

Filipe B Rodrigues^{1†}, Lauren M Byrne^{1†}, Alexander J Lowe¹, Rosanna Tortelli¹, Mariette Heins², Gunnar Flik², Eileanoir B Johnson¹, Enrico De Vita^{3,4}, Rachael I Scahill¹, Flaviano Giorgini⁵ and Edward J Wild^{1*}

- 1 UCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK
- 2 Charles River Laboratories, Groningen, the Netherlands
- 3 Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK
- 4 Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, UK
- 5 Department of Genetics and Genome Biology, University of Leicester, Leicester, UK

Running title: Kynurenine pathway in Huntington's disease

[†] These authors contributed equally as first authors of this study

^{*} Dr Edward J Wild, e.wild@ucl.ac.uk, UCL Huntington's Disease Centre, University College London, 10-12 Russell Square, London WC1B 5EH

Abstract

Background:

Converging lines of evidence from cell, yeast and animal models, and post-mortem human brain tissue studies, support the involvement of the kynurenine pathway (KP) in Huntington's disease (HD) pathogenesis. Quantifying KP metabolites in HD biofluids is desirable, both to study pathobiology, and as a potential source of biomarkers to quantify pathway dysfunction and evaluate the biochemical impact of therapeutic interventions targeting its components.

Methods:

In a prospective single-site controlled cohort study with standardised collection of CSF, blood, phenotypic and imaging data, we used high-performance liquid-chromatography to measure the levels of KP metabolites – tryptophan, kynurenine, kynurenic acid, 3-hydroxykynurenine, anthranilic acid and quinolinic acid – in CSF and plasma of 80 participants (20 healthy controls, 20 premanifest HD, and 40 manifest HD). We investigated short-term stability, intergroup differences, associations with clinical and imaging measures, and derived sample-size calculation for future studies.

Findings:

Overall, KP metabolites in CSF and plasma were stable over 6 weeks, displayed no significant group differences and were not associated with clinical or imaging measures. Larger sample sizes would be needed to show differences in future studies.

Interpretation:

We conclude that the studied metabolites are readily and reliably quantifiable in both biofluids in controls and HD gene expansion carriers. However, we found little evidence to support a substantial derangement of the KP in HD, at least to the extent that it is reflected by the levels of the metabolites in patient-derived biofluids.

Fund:

This study was supported by the Medical Research Council UK and CHDI foundation.

Keywords

Huntington Disease, Biomarkers, Kynurenine, Cerebrospinal Fluid, Blood, Cohort Studies

Research in Context Section

Evidence before this study

The kynurenine pathway is a metabolic process needed for the degradation of tryptophan – an essential amino acid. Several by-products of this pathway have been implicated in the pathobiology of Huntington's disease, a fatal neurodegenerative condition. Studying these metabolites could help better understand the biology of the condition and accelerate treatment development. In 2018, a systematic review concluded that only a small number of studies attempted to investigate the levels of these by-products in human biofluids, with the majority being limited by methodologic frailties and therefore requiring further study.

Added value of this study

We used a large prospective cohort consisting of Huntington's disease mutation carriers and healthy controls to study the metabolic by-products of the kynurenine pathway. Matched cerebrospinal fluid and blood were collected using standardized protocol and analysed with high-performance liquid-chromatography. None of the studied metabolites showed associations with disease stage or with well-known clinical and imaging markers of the disease.

Implication of all the available evidence

Our results show that substantial alterations of the kynurenine pathway are not present in patients with Huntington's disease compared to healthy controls, at least to the extent that is measurable in cerebrospinal fluid or blood. Whilst our results discourage the use of these metabolites as diagnostic and prognostic biomarkers, they do not reject the notion that regional- and tissue-specific alterations may exist, and that they may possess value as pharmacodynamic biomarkers in clinical trials targeting the kynurenine pathway.

Introduction

Huntington's disease (HD) is an invariably fatal neurodegenerative disease caused by CAG repeat expansions in the *HTT* gene. Inherited in an autosomal dominant manner, the polyglutamine expansion results in the ubiquitous expression of a mutant form of huntingtin protein (mHTT) (2), causing a diverse array of intracellular toxicities and derangement of downstream pathways. With no treatments shown to prevent, slow or reverse its progression (3), extensive dysfunction and neuronal death occurs. Although characterized by the degeneration of striatal medium spiny neurons (MSNs), widespread damage involving most brain regions is observed (4). In addition to its expression in glial cells and neurons, mHTT is expressed in the peripheral nervous system (5). The interplay amongst different cell types, both central and peripheral, and the dynamics of dysfunction versus compensation, are increasingly recognised as contributing to the complex pathogenesis of HD (6-8).

Early animal models used excitotoxins such as quinolinic acid (QUIN), injected into the striatum, to recapitulate specific cellular pathology and phenotypic features of HD (9, 10). Although influential, chemically-lesioned models have now largely been superseded by various transgenic animals (11). The observed selective vulnerability of striatal MSNs to such toxins led to the theory that excitotoxicity may be an inherent part of HD pathogenesis, a theory that remains of interest.

QUIN is produced in the central nervous system by microglial cells, as one endpoint of the kynurenine pathway (KP) of tryptophan (TRP) degradation (Figure 1 Overview of the kynurenine pathway. Adapted with authors and editors' permission (1). The designations 'neurotoxic' and 'neuroprotective' are assigned on the basis of the balance of evidence and are acknowledged to be simplifications of complex properties.

Figure 1) (1), ultimately leading to the formation of the coenzyme nicotinamide adenine dinucleotide (NAD+). In addition to promoting excitotoxicity via activation of *N*-methyl-D-aspartate (NMDA) receptors, QUIN is a potent free radical generator (12). Several additional KP metabolites have been found to be neuroactive, including 3-hydroxykynurenine (3-HK) and kynurenic acid (KYNA). 3-HK is broadly neurotoxic via generation of free radicals (13-15), whereas KYNA displays neuroprotective properties via antagonism of excitatory amino acid receptors and scavenging of free radicals (16-19). The absolute levels of these metabolites, as well as the ratio of the neurotoxic compounds relative to KYNA, may be of value when considering progression of neurodegenerative disorders such as HD. Furthermore, the activities of the key KP regulatory enzymes kynurenine-3-monooxygenase (KMO) – which synthesizes 3-HK leading to downstream formation of QUIN - and the kynurenine aminotransferases (KATs) which synthesize KYNA – are equally important (1).




Figure 1 Overview of the kynurenine pathway. Adapted with authors and editors' permission (1). The designations 'neurotoxic' and 'neuroprotective' are assigned on the basis of the balance of evidence and are acknowledged to be simplifications of complex properties.

Figure 2 Overview of the kynurenine pathway. Adapted with authors and editors' permission (1). The designations 'neurotoxic' and 'neuroprotective' are assigned on the basis of the balance of evidence and are acknowledged to be simplifications of complex properties.

Converging lines of evidence support the involvement of the KP in HD pathogenesis. In post-mortem brain tissue obtained from HD patients, QUIN and 3-HK levels are increased and KYNA levels reduced (20-22). In the R6/2 mouse model, KMO activity has shown to be increased (23); however, recent work in a HD patient cohort failed to replicate these findings (Vonsattel neuropathology grades 1 through 4)(22). Furthermore, inhibition of KMO has demonstrated beneficial effects in multiple studies. In HD mouse models, peripheral KMO inhibition improves disease-relevant phenotypes (24, 25), while genetic inhibition is strongly protective in HD model yeast (26) and *Drosophila* (27-29). Consequently, pharmacological inhibition of KMO is considered a promising target for HD therapeutic development (1, 30).

Evidence of KP involvement in living human patients is limited. Blood and cerebrospinal fluid (CSF) are accessible biofluids that offer insights into comparative derangements in the periphery and CNS, and are sources of useful biomarkers in HD (31-33); however evidence on the KP in these fluids in HD is limited and conflicting. Early work examining CSF identified no difference in CSF QUIN levels in 10 HD patients versus 7 schizophrenic controls (34). This was further supported by Heyes *et al.* who observed no significant differences in CSF QUIN in 9 HD patients compared to 9 hospital patients using electron capture negative chemical ionization mass spectrometry and gas chromatography (35). In contrast with QUIN, levels of CSF kynurenine and KYNA were shown to be mildly reduced in 13 HD patients compared to 7 healthy controls (36).

Notably, all previous published human studies of the KP in HD CSF pre-date the discovery of the causative genetic mutation, used small sample numbers and were largely uncontrolled for important sources of variability like time of day, fasting status, CSF processing methods and source of control CSF(37).

Quantifying KP metabolites in HD CSF remains desirable, both to study pathobiology in human patients, and as a potential source of biomarkers to quantify pathway dysfunction and the biochemical impact of therapeutic interventions targeting its components. Therefore, we sought to combine modern analytical methods, with CSF and matched blood plasma, collected and processed under strictly standardised conditions, from a large (n = 80) prospective cohort of gene expansion carriers and matched controls (32, 38). Using high-performance liquid-chromatography (HPLC) with tandem mass spectroscopy (MS/MS) quantification methods, we measured levels of six KP metabolites (Figure 1 Overview of the kynurenine pathway. Adapted with authors and editors' permission (1). The designations 'neurotoxic' and 'neuroprotective' are assigned on the basis of the balance of evidence and are acknowledged to be simplifications of complex properties.

Figure 1) – tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK), anthranilic acid (AA) and quinolinic acid (QUIN) – in CSF and blood plasma, and applied a pre-defined statistical analysis plan to investigate the hypothesis that KMO activity is important to HD pathogenesis. As a pre-defined secondary analysis, we examined ratios of metabolites that may be informative of the activity of key enzymes in the pathway. Finally, we undertook an exploratory analysis of all metabolites in CSF and plasma in HD and controls.

Methods

Study design

The HD-CSF study was a prospective single-site controlled cohort study with standardised collection of CSF, blood and phenotypic data (online protocol: DOI: 10.5522/04/11828448.v1). Eighty participants were recruited (20 healthy controls, 20 premanifest HD [PreHD], and 40 manifest HD). All phenotypic assessment measures were predefined for HD-CSF based on metrics shown to have the largest effect sizes for predicting HD progression(39). Baseline assessments were conducted from February 2016 to February 2017(32). At baseline, 15 (19%) participants underwent an optional repeat sampling 4-8 weeks after baseline, permitting the assessment of within-subject short-term metabolite stability. MRI brain imaging, an optional component, was completed by 64 participants (80%).

Ethical approval

This study was performed in accordance with the principles of the Declaration of Helsinki, and the International Conference on Harmonization Good Clinical Practice standards. Ethical approval was obtained from the London Camberwell St Giles Research Ethics Committee (15/LO/1917). Prior to undertaking study procedures, all participants gave informed consent which was obtained by clinical staff.

Participants

Manifest HD participants were defined as adults having a Unified Huntington's Disease Rating Scale (UHDRS) diagnostic confidence level (DCL) of 4 and HTT CAG repeat count \geq 36. PreHD participants had CAG \geq 40 and DCL < 4. Healthy controls were age- and gendermatched to gene expansion carriers, mostly spouses or gene-negative siblings of HD gene expansion carriers and with no neurological signs or symptoms. All were recruited from the National Hospital for Neurology & Neurosurgery Huntington's Disease Service or the University College London Huntington's Disease Centre research databases.

Clinical assessments

Motor, cognitive and functional status were assessed using the UHDRS from the core Enroll-HD battery(40), including: the UHDRS Total Motor Score (TMS), Total Functional Capacity (TFC), Symbol Digit Modalities Test (SDMT), Stroop Word Reading (SWR), Stroop Color Naming (SCN) and Verbal Fluency – Categorical (VFC). These were performed at either a screening visit before sampling or an associated Enroll-HD visit (https://www.enroll-hd.org) within the 2 months prior to screening. We employed a calibrated iteration of the composite UHDRS (cUHDRS)(41, 42). Disease burden score (DBS) was calculated for each gene expansion carrier using the formula: $[CAG - 35.5] \times age(43)$. DBS estimates cumulative HD pathology as a function of CAG and the time exposed to the effects of the pathologic mutation, and has been shown to predict several features of disease progression including striatal pathology(39, 43).

Biosample collection and processing

CSF and matched plasma were obtained as previous described (32). All collections were standardised for time of day after overnight fasting and processed within 30 minutes of collection using standardised equipment. Blood was collected within 10 minutes of CSF and processed to plasma. Biosamples were frozen and stored at -80°C until quantification.

Kynurenine pathway metabolite quantification

KP metabolites were quantified by Charles River Laboratories (the Netherlands) using a high-performance liquid-chromatography (HPLC) with tandem mass spectroscopy (MS/MS) detection method (LC-MC) published previously (24). D₅-TRP, D₄-KYN, D₅-KYNA, ¹³C₆-3-HK, D₄-AA and a D₃-QUIN were used as internal standards. An aliquot of a solution containing the internal standard was mixed with an aliquot of each experimental sample to generate an LC-MS sample. An aliquot of each LC-MS sample was injected into the HPLC system by an automated sample injector (SIL20-AD, Shimadzu, Japan). Chromatographic separation was performed using a reversed phase analytical column, configured as per *Table 1*, with elution performed using a linear gradient. MS analyses were performed using an API 4000 MS/MS system consisting of an API 4000 MS/MS detector and a Turbo Ion Spray interface (Applied Biosystems, USA). The acquisitions on API 4000 were performed in positive ionization mode, with optimized settings for the analytes. The instrument was operated in multiple-reaction-monitoring (MRM) mode. Data were calibrated and quantified using the AnalystTM data system (Applied Biosystems, USA).

Assays were performed blinded to clinical data and in a continuous run with the same quality control samples (QCs) to confirm performance over time. Each sample was measured once. The acceptance criteria for CSF assays was +/- 25% accuracy for the low limits of quantification (LoQ) calibrator and QC-low, and +/- 20% accuracy for all other calibrators and QC-mid and -high. For plasma assays, acceptance criteria were 5% wider. Individual runs were accepted when > 66% of QC's were within criteria as described above (> 50% on individual level). The LoQ, frequency of samples below LoQ, and frequency of rejected samples due to quality criteria are shown in *Table 1*.

Table 1 Chromatographic separation parameters for each metabolite and assay performance. Note that 2 manifest HD participants are missing plasma. 3-HK, 3-hydroxykynurenine; AA, anthranilic acid; ACN; acetonitrile; C, cerebrospinal fluid; FA, formic acid; H_2O , ultra-purified water; KYN, kynurenine; KYNA, kynurenic acid; P, plasma; QUIN, quinolinic acid; TFA, trifluoroacetic acid; TRP, tryptophan.

Metabolite	Column	Particle	Temperature	Mobile phase A	Mobile phase B	Elution	Low limit of	n (%)	n (%)
	size	size	(° C)			flow rate	quantification	below	quality
	(mm)	(µm)				(ml/min)	(LoQ)	LoQ	rejected
TRP	100 x 3	2.5	5	$H_2O + 0.1\% FA$	ACN + 0·1% FA	0.3	C: 500 nM	C: 0/95 (0%)	C: 0/95 (0%)
				2			P: 500 nM	P: 0/93 (0%)	P: 0/93 (0%)
KYN	150 x 2.1	3	25	H ₂ O + 0·1% FA	ACN + 0·1% FA	0.2	C: 2.5 nM	C: 0/95 (0%)	C: 0/95 (0%)
				2			P: 0.5 μM	P: 0/93 (0%)	P: 0/93 (0%)
KYNA	150 x 2.1	3	25	$H_2O + 0.1\% FA$	ACN + 0·1% FA	0.2	C: 0.25 nM	C: 0/95 (0%)	C: 0/95 (0%)
				-			P: 15.0 nM	P: 4/93 (4%)	P: 4/93 (4%)
3-HK	150 x 2.1	3	25	H ₂ O + 0·1% FA	ACN + 0·1% FA	0.2	C: 0.25 nM	C: 0/95 (0%)	C: 0/95 (0%)
				2			P: 5.0 nM	P: 1/93 (1%)	P: 0/93 (0%)
AA	150 x 2.1	3	25	H ₂ O + 0·1% FA	ACN + 0·1% FA	0.2	C: 1.25 nM	C: 0/95 (0%)	C: 0/95 (0%)
							P: 5.0 nM	P: 7/93 (8%)	P: 0/93 (0%)
QUIN	100 x 3	2.5	35	H ₂ O + 0·2% TFA	ACN + 0·2% TFA	0.3	C: 1.0 nM	C: 0/95 (0%)	C: 0/95 (0%)
							P: 100 nM	P: 1/93 (1%)	P: 0/93 (0%)

MRI Acquisition

T1-weighted MRI data were acquired on a 3T Siemens Prisma scanner using a protocol optimized for this study. Images were acquired using a 3D magnetization-prepared 180 degrees radio-frequency pulses and rapid gradient-echo (MPRAGE) sequence with a repetition time (TR) =2000 ms and echo time (TE)=2.05 ms. The protocol had an inversion time of 850 ms, flip angle of 8 degrees, matrix size 256 x 240 mm. 256 coronal partitions were collected to cover the entire brain with a slice thickness of 1·0 mm. Parallel imaging acceleration (GeneRalized Autocalibrating Partial Parallel Acquisition [GRAPPA], acceleration factor [R]=2) was used and 3D distortion correction was applied to all images.

MRI Processing

All T1-weighted scans passed visual quality control check for the presence of significant motion or other artefacts before processing. Bias correction was performed using the N3 procedure (44). A semiautomated segmentation procedure via Medical Image Display Analysis Software (MIDAS) was used to generate volumetric regions of the whole brain and total intracranial volume (TIV), as previously described (45-47). SPM12 "Segment" (MATLAB version 2012b) was used to measure the volume of the grey and white matter (48). Multi-Atlas Propagation with EM Refinement (MALP-EM) was used to quantify caudate volume (49). MALP-EM is an automated tool used to segment MRI scans into regional volumes and has previously been validated for use in HD cohorts (50). Default settings were used for both SPM12 segmentations and MALP-EM caudate regions. No scans failed processing after visual quality control of segmentations by experienced raters to ensure accurate delineation of the regions. Baseline MRI volumes were presented adjusted for TIV. All MRI analyses used brain volumes as percentage of TIV.

Statistical analyses

Statistical analysis was performed with Stata MP 16 software (StataCorp, USA). To minimise type 1 errors (i.e. rejection of true null hypotheses) resulting from multiplicity, we predefined CSF levels of KYNA, 3-HK and QUIN as primary outcomes, hypothesising that quantifiable differences would be apparent if the KP is dysregulated in HD. The ratios of CSF 3-HK:KYNA, KYNA:KYN and 3-HK:KYN were secondary outcomes, hypothesised to reflect the overall balance of the key neuroprotective and neurotoxic metabolites, the activity of the KATs, and the activity of KMO respectively (Figure 1 Overview of the kynurenine pathway. Adapted with authors and editors' permission (1). The designations 'neurotoxic' and 'neuroprotective' are assigned on the basis of the balance of evidence and are acknowledged to be simplifications of complex properties.

Figure 1). Analyses of all other CSF and plasma metabolites were exploratory. Measurements below the LoD for the metabolites of interest were assumed as missing - no imputation was used. Analyte distributions were visually assessed and if necessary, arithmetical transformations were applied to meet model assumptions (Figure S1-3). Continuous variables were reported as mean ± standard deviations (SD); and categorical variables as absolute (n) and relative frequencies (%). Associations with age (healthy controls only), gender, CAG repeat count (gene expansion carriers only) and haemoglobin (in case of CSF metabolites only) and time in freezer storage were visually assessed for all outcomes (Figure S4-6). Due to its known effects on HD, all models included age as covariate.

As a planned second-level analysis, to assess associations with measures beyond the known combined effect of age and *HTT* CAG repeat count, models including gene expansion

carriers only were run with age and CAG repeat count as covariates. To investigate intergroup differences in outcomes of interest, we applied generalised linear regression models estimated via ordinary least squares. Models were fitted with the variable of interest as the dependent variable, and first with age and group membership, and then with age and CAG and group membership as independent variables. We report results for the omnibus group membership main effect test and relevant contrasts (i.e. healthy controls vs PreHD and PreHD vs manifest HD). Other comparisons (i.e. healthy controls vs manifest HD) were not undertaken as we treat HD as a biological continuum. To investigate alterations unique to later stages of the disease we used clinical measures of disease progression (cUHDRS) and/or cumulative mHTT toxicity (DBS). Tests were not adjusted for multiple comparisons but the statistical approach was designed to minimise multiplicity within each question of independent interest.

We used Pearson's partial correlations adjusted for age, and for age and CAG to study associations between outcomes of interest and DBS, clinical and imaging measures in gene expansion carriers. Pearson's correlations were used to study associations between metabolites in CSF and plasma. Bias-corrected and accelerated bootstrapped 95% confidence intervals (95% CI) were calculated for correlation coefficients. We calculated interclass-correlation coefficients (ICC) and 95% CI using two-way mixed-effects models to investigate within-subject short-term stability. Sample size calculations for two 2-group comparisons (i.e. healthy control vs PreHD and PreHD vs manifest HD) using 2-sided Student t-tests were performed to inform future studies using the detected effect sizes adjusted for age in primary and secondary outcomes, and assuming a 5% type 1 error and 20% type 2 error (80% power). No adjustments were made for multiplicity.

Role of funding source

Funders had no role in study design, data collection, analysis, or interpretation, or writing of the report. The corresponding author had full access to data and final responsibility for the decision to submit for publication.

Results

Demographics

Eighty participants were recruited - all contributed with CSF and 2 (3%) manifest HD were missing plasma. Full cohort characteristics are presented in Table S1. Disease groups were well-matched for gender and differed as expected in clinical, cognitive and imaging measures. Age differed significantly between groups due to the control group (50·68 years \pm 11·0) being matched to all gene expansion carriers, and manifest HD (56·02 years \pm 9·36) being more advanced in their disease course than preHD (42·38 years \pm 11·04), as previously reported(32, 38).

Primary outcomes

All three primary outcomes – CSF KYNA, 3-HK and QUIN - were associated with age in healthy controls, but not with gender, CAG repeat count (gene expansion carriers only), CSF haemoglobin or time in freezer storage (Figure S4). Age- and age and CAG-adjusted CSF levels of KYNA, 3-HK and QUIN showed no significant difference between groups (*Figure 3*; *Table 2*).




Figure 3 Intergroup differences (top row), associations with Disease Burden Score (DBS, second row) and composite Unified Huntington's Disease Rating Scale (cUHDRS, third row), and within-subject short-term stability (bottom row) for primary outcomes: cerebrospinal fluid (CSF) kynurenic acid (KYNA), CSF 3-hydroxykynurenine (3-HK) and

CSF quinolinic acid (QUIN). Associations were not found in any of the analyses. Grey represents healthy controls, light orange preHD and dark orange HD.

Table 2 Intergroup comparisons. Note that for outcomes where a transformation including a reciprocal (i.e. 1/x), an increase in the raw measurement corresponds to a decreased in the transformed value and vice-versa. 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid; CSF, cerebrospinal fluid; HC, healthy controls; KYN, kynurenine; KYNA, kynurenic acid; M, manifest HD; N/A, not applicable; PM, premanifest HD; QUIN, quinolinic acid; SD, standard deviation; TRP, tryptophan.

	Heal	thy Contro		Prei	nanifest Hl		Man	ifest HD		Adjusted for	Group	HC vs PM	PM vs M
	n	Mean	SD	n	Mean	SD	n	Mean	SD		membership		
Primary Outcomes													
CSF KYNA	20	0.98	0.46	20	0.80	0.50	40	1.29	0.50	Age	0.154	0.910	0.113
log(nM)										Age and CAG	N/A	N/A	0.253
CSF 3-HK	20	0.35	0.16	20	0.33	0.15	40	0.32	0.12	Age	0.383	0.199	0.231
1/nM										Age and CAG	N/A	N/A	0.034
CSF QUIN	20	0.23	0.05	20	0.25	0.06	40	0.23	0.05	Age	0.312	0.905	0.206
$1/\sqrt{nM}$										Age and CAG	N/A	N/A	0.156
Secondary Outcomes		-1	-1.		"	<u>'</u>		<u> </u>	•			1	
CSF 3-HK:KYNA	20	0.95	0.27	20	0.85	0.24	40	1.05	0.25	Age	0.094	0.371	0.036
1/√ratio										Age and CAG	N/A	N/A	0.007
CSF KYNA:KYN	20	-2.79	0.36	20	-2.87	0.33	40	-2.49	0.33	Age	0.005	0.830	0.007
log(ratio)										Age and CAG	N/A	N/A	0.027
CSF 3-HK:KYN	20	238-82	143.04	20	186-91	109.88	40	209.78	113.86	Age	0.445	0.223	0.629
$1/(ratio^2)$										Age and CAG	N/A	N/A	0.109
Exploratory Outcome	:S			1						1 0	I.	1	
CSF TRP	20	2.16	0.42	20	2.0	0.45	40	2.05	0.35	Age	0.265	0.980	0.196
nM										Age and CAG	N/A	N/A	0.391
CSF KYN	20	0.15	0.03	20	0.16	0.03	40	0.15	0.02	Age	0.836	0.932	0.682
$1/\sqrt{nM}$										Age and CAG	N/A	N/A	0.699
CSF AA	20	0.92	0.29	20	0.87	0.37	40	0.94	0.27	Age	0.676	0.682	0.386
log(nM)										Age and CAG	N/A	N/A	0.641
Plasma TRP	20	7.11	0.81	20	7.18	0.77	38	7.00	0.51	Age	0.642	0.730	0.368
\sqrt{nM}										Age and CAG	N/A	N/A	0.517
Plasma KYN	20	0.62	0.26	20	0.66	0.24	38	0.60	0.24	Age	0.408	0.453	0.183
$log(\mu M)$										Age and CAG	N/A	N/A	0.058
Plasma KYNA	19	4.07	0.33	19	4.13	0.42	32	3.96	0.32	Age	0.201	0.516	0.086
log(nM)										Age and CAG	N/A	N/A	0.032
Plasma 3-HK	19	3.67	0.24	20	3.58	0.29	38	3.58	0.29	Age	0.442	0.493	0.664
log(nM)										Age and CAG	N/A	N/A	0.304
Plasma AA	18	0.36	0.05	16	0.36	0.05	37	0.34	0.06	Age	0.451	0.500	0.710
$1/\sqrt{nM}$										Age and CAG	N/A	N/A	0.440
Plasma QUIN	20	5.85	0.36	19	5.80	0.42	38	5.74	0.32	Age	0.148	0.722	0.087
log(nM)										Age and CAG	N/A	N/A	0.061

Associations between age-adjusted CSF levels of KYNA, 3-HK or QUIN and DBS, clinical and imaging measures were negligible to weak (*Figure 4*, Table S2 and Figure S8).




Figure 4 Associations between outcomes and clinical and imaging measures for primary, secondary and exploratory outcomes in gene expansion carriers. Numbers are Pearson's partial correlations coefficients adjusted for age (top row), and for age and CAG (bottom row; see Table S2 for 95% CI and Figure S8 for scatter plots). 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid; CSF, cerebrospinal fluid; cUHDRS, composite Unified Huntington's Disease Rating Scale; KYN, kynurenine; KYNA, kynurenic acid; QUIN, quinolinic acid; SCN, Stroop Color Naming; SDMT, Symbol Digit Modalities Test; SWR, Stroop Word Reading; TFC, UHDRS Total Functional Capacity; TMS, UHDRS Total Motor Score; TRP, tryptophan; VFC, Verbal Fluency – Categorical.

Within-subject short-term stability was good for CSF KYNA (ICC 0·84, 95% CI 0·58 to 0·94) and QUIN (ICC 0·90, 95% CI 0·72 to 0·96), and moderate for 3-HK (ICC 0·68, 95% CI 0·27 to 0·88, *Figure 3* and Table S3).

Power calculations showed that the number of participants per arm needed to give 80% power to detect a difference at the alpha level of 0.05 in age-adjusted CSF levels between healthy controls and preHD would be 48,921 for KYNA, 376 for 3-HK and 43,665 for

QUIN. For the comparison between preHD and HD the number would be 368 for KYNA, 648 for 3-HK and 579 for QUIN.

Secondary outcomes

None of the three pre-defined ratios of interest – CSF 3-HK:KYNA, KYNA:KYN and 3-HK:KYN - were associated with age, gender, CAG repeat count, CSF haemoglobin or time in the freezer (Figure S5). Age- and age and CAG-adjusted CSF levels of 3-HK:KYNA, KYNA:KYN and 3-HK:KYN showed no difference between healthy controls and preHD (*Figure 5*; *Table 2*). There were differences in ratios of 3-HK:KYNA and KYNA:KYN between preHD and manifest HD (age-adjusted p-values = 0.036 and 0.007, respectively; age- and CAG-adjusted p-values = 0.007 and 0.027, respectively). No differences were found for 3-HK:KYN.




Figure 5 Intergroup differences (top row), associations with Disease Burden Score (DBS, second row) and composite Unified Huntington's Disease Rating Scale (cUHDRS, third row), and within-subject short-term stability (bottom row) for secondary outcomes: ratios of cerebrospinal fluid (CSF) 3-hydroxykynurenine to kynurenic acid (3-HK:KYNA), CSF kynurenic acid to kynurenine (KYNA:KYN) and CSF 3-hydroxykynurenine to kynurenine (3-HK:KYN). Note that for outcomes where a transformation including a reciprocal (i.e. 1/x), an increase in the raw measurement corresponds to a decreased in the transformed value and vice-versa. Grey represents healthy controls, light orange preHD and dark orange HD.

Associations between age-adjusted CSF ratios and DBS, clinical and imaging measures were negligible to weak for 3-HK:KYNA, weak for KYNA:KYN, and weak to moderate for 3-HK:KYN (

Figure 4, Table S2 and Figure S8).

Within-subject short-term stability was good for 3-HK:KYNA (ICC 0·78, 95% CI 0·46 to 0·92) and 3-HK:KYN (ICC 0·78, 95% CI 0·47 to 0·92), and weak to moderate for KYNA:KYN (ICC 0·43, 95% CI -0·09 to 0·76, *Figure 5* and Table S3).

Power calculations showed that the number of participants per arm needed to give 80% power to detect a difference at the alpha level of 0.05 in age-adjusted CSF levels between healthy controls and preHD would be 777 for 3-HK:KYNA, 13,521 for KYNA:KYN and 417 for 3-HK:KYN. For the comparison between preHD and HD the number would be 207 for 3-HK:KYNA, 126 for KYNA:KYN and 3,993 for 3-HK:KYN.

Exploratory outcomes

Associations between age, gender, CAG repeat count, CSF haemoglobin or time in the freezer are shown in Figure S6. Age- and age and CAG-adjusted levels of CSF and plasma exploratory outcomes showed no difference between groups (Figure S7 and *Table 2*). While plasma KYN, 3-HK, AA and QUIN showed negligible to weak associations with DBS, clinical and imaging measures; CSF AA showed negligible to moderate associations, and CSF TRP, KYN, and plasma TRP and KYNA showed weak to moderate associations (Figure S7, Figure S8 and Table S2). Within-subject short-term stability varied from low (plasma KYNA) to high (plasma QUIN) and is summarised in Table S3.

Association between CSF and plasma

The matched CSF and plasma analytes were associated, with the exception of KYNA (*Figure 6* and Table S4). The strongest association was seen for QUIN (r = -0.75, 95% CI -0.83 to -0.65).




Figure 6 Associations between CSF and plasma. Grey represents healthy controls, light orange preHD and dark orange HD.

Discussion

In this comprehensive study of KP metabolites in CSF and plasma in HD, we found that TRP, KYN, KYNA, 3-HK, AA and QUIN were readily and reliably quantifiable in both biofluids in controls and gene expansion carriers. However, we found little evidence to support a substantial derangement of the KP in HD, at least to the extent that it is reflected by the levels of the metabolites in patient-derived biofluids.

None of the three CSF metabolites we pre-specified as being of particular interest – KYNA, 3-HK and QUIN – had a significantly altered level in preHD or HD. We found no association between CSF levels of these metabolites and any robust clinical, cognitive and MR brain volumetric measures.

We did find significant associations between all three and age, which might (along with lesser assay reliability and sample quality) be one reason why previous studies reported some alterations, albeit inconsistently. Careful examination and adjustment for confounding variables is especially important given that HD is characterised by an extended premanifest period followed by a long period of manifest disease. This tends to make premanifest cohorts younger than those with manifest HD, and makes it very challenging to recruit a control group that matches the HD groups well for age. We previously showed that an apparent increase in CSF TREM2 in HD was in fact an artefact of its relationship with age (51).

We pre-defined three CSF metabolite ratios that might change in the presence of specific predicted derangements of the KP – 3-HK:KYNA as a reflection of the ratio of the main protective and neurotoxic metabolites whose synthetic enzymes have been implicated in HD; KYNA:KYN as a measure of the activity of the KATs and 3-HK:KYN as a measure of the activity of KMO. We found no evidence for altered CSF 3-HK:KYN ratio. While there was no evidence of CSF 3-HK:KYNA and KYNA:KYN ratio differences between healthy controls and pre-HD, HD seems to have lower 3-HK:KYNA ratio than preHD (shown as a higher 1/√ratio) and higher KYNA:KYN (shown as a higher log(ratio)), differences that remained significant after adjustment for age and CAG. Note that for outcomes where a transformation including a reciprocal (i.e. 1/x), an increase in the raw measurement corresponds to a decreased in the transformed value and vice-versa. This suggests that the activity of KATs may be increased in HD, an increase that appears to grow as the disease progresses. This may reflect a primary effect of the HD mutation on KATs, or compensatory overactivity because of alterations in the central KP.

As expected, the CSF and plasma levels of each metabolite were significantly associated, and the plasma levels of each were higher, in line with previous reports in Alzheimer's disease and depression.(52, 53)

Though largely negative, our findings do not imply that the KP in general, or KMO in particular, is not a valid therapeutic target. It is possible that cell-specific or region-specific disease-related alterations in this pathway contribute substantially to the pathogenesis of HD and that pharmacologically correcting them could favourably modify the course of the disease. In that context, it is therefore still possible that measuring KP metabolite levels in CSF could provide one or more valuable readouts of target engagement or meaningful biological effect, for instance by increasing the level of protective substances to above the baseline or control level. The non-significant, small differences between groups could also prove robust if tested in a much larger sample set; we have offered sample size calculations

for such an experiment. Overall, however, this study provides little support for a relevant alteration of kynurenine pathway function in HD that is biochemically detectable in accessible patient biofluids.

Contributors

EJW designed the study with the input of FG. FBR and LMB were involved in participant recruitment. Eligibility, clinical examinations and sample collection were performed by FBR, LMB, and RT. Imaging assessments were conceived RIS, EBJ and EDV, data was acquired by EDV, MA, EBJ, and processed by RIS and EBJ. MM and GF processed and analysed the patient samples. FBR developed and performed the statistical analysis; FBR, AJL and EJW interpreted the data and wrote the manuscript; and all authors contributed to reviewing the manuscript.

Declaration of interests

FBR, LMB, AJL, RT, EBJ, RIS, EJW are University College London employees. MA is a University College London Hospitals NHS Foundation Thrust employee. EDV is a King's College London employee. MH and GF are full-time employees of Charles River Laboratories. FG is an employee of the University of Leicester. FBR has provided consultancy services to GLG and F. Hoffmann-La Roche Ltd. LMR has provided consultancy services to GLG, F. Hoffmann-La Roche Ltd, Genentech and Annexon. RIS has undertaken consultancy services for Ixico Ltd. EJW reports grants from Medical Research Council (MRC), CHDI Foundation, and F. Hoffmann-La Roche Ltd during the conduct of the study; personal fees from Hoffman La Roche Ltd, Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda, Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust, has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals. This study was supported in part by a project grant from the MRC (MR/N00373X/1) awarded to FG.

Acknowledgements

We would like to thank all the participants from the HD community who donated samples and gave their time to take part in this study. This study was supported by the Medical Research Council UK and CHDI foundation.

Data Sharing Statement

The data that support the findings of this study are available on request from the corresponding author, EJW. The data are not publicly available due to their containing information that could compromise the privacy of research participants.

Figures

Figure 1 Overview of the kynurenine pathway. Adapted with authors and editors' permission (1). The designations 'neurotoxic' and 'neuroprotective' are assigned on the basis of the balance of evidence and are acknowledged to be simplifications of complex properties. 5 Figure 1 Overview of the kynurenine pathway. Adapted with authors and editors' permission (1). The designations 'neurotoxic' and 'neuroprotective' are assigned on the basis of the balance of evidence and are acknowledged to be simplifications of complex properties. 5 Figure 2 Intergroup differences (top row), associations with Disease Burden Score (DBS, second row) and composite Unified Huntington's Disease Rating Scale (cUHDRS, third row), and within-subject short-term stability (bottom row) for primary outcomes: cerebrospinal fluid (CSF) kynurenic acid (KYNA), CSF 3-hydroxykynurenine (3-HK) and CSF quinolinic acid (OUIN). Associations were not found in any of the analyses. Grey Figure 3 Associations between outcomes and clinical and imaging measures for primary, secondary and exploratory outcomes in gene expansion carriers. Numbers are Pearson's partial correlations coefficients adjusted for age (top row), and for age and CAG (bottom row; see Table S2 for 95% CI and Figure S8 for scatter plots). 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid; CSF, cerebrospinal fluid; cUHDRS, composite Unified Huntington's Disease Rating Scale; KYN, kynurenine; KYNA, kynurenic acid; OUIN, quinolinic acid; SCN, Stroop Color Naming; SDMT, Symbol Digit Modalities Test; SWR, Stroop Word Reading; TFC, UHDRS Total Functional Capacity; TMS, UHDRS Total Motor Score; TRP, Figure 4 Intergroup differences (top row), associations with Disease Burden Score (DBS, second row) and composite Unified Huntington's Disease Rating Scale (cUHDRS, third row), and within-subject short-term stability (bottom row) for secondary outcomes: ratios of cerebrospinal fluid (CSF) 3-hydroxykynurenine to kynurenic acid (3-HK:KYNA), CSF kynurenic acid to kynurenine (KYNA:KYN) and CSF 3-hydroxykynurenine to kynurenine (3-HK:KYN). Note that for outcomes where a transformation including a reciprocal (i.e. 1/x), an increase in the raw measurement corresponds to a decreased in the transformed value and vice-versa. Grey represents healthy controls, light orange preHD and dark orange HD..... 16 Figure 5 Associations between CSF and plasma. Grey represents healthy controls, light

Tables

Table 1 Chromatographic separation parameters for each metabolite and assay performance. Note that 2 manifest HD participants are missing plasma. 3-HK, 3-hydroxykynurenine; AA, anthranilic acid; ACN; acetonitrile; C, cerebrospinal fluid; FA, formic acid; H₂O, ultra-purified water; KYN, kynurenine; KYNA, kynurenic acid; P, plasma; QUIN, quinolinic acid; TFA, trifluoroacetic acid; TRP, tryptophan.

Table 2 Intergroup comparisons. Note that for outcomes where a transformation including a reciprocal (i.e. 1/x), an increase in the raw measurement corresponds to a decreased in the transformed value and vice-versa. 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid; CSF, cerebrospinal fluid; HC, healthy controls; KYN, kynurenine; KYNA, kynurenic acid; M, manifest HD; N/A, not applicable; PM, premanifest HD; QUIN, quinolinic acid; SD, standard deviation; TRP, tryptophan.

References

- 1. Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Seminars in cell & developmental biology. 2015;40:134-41.
- 2. McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018;25(1):24-34.
- 3. Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ. Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. J Huntingtons Dis. 2017;6(2):157-63.
- 4. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.
- 5. van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009;8(8):765-74.
- 6. Wood TE, Barry J, Yang Z, Cepeda C, Levine MS, Gray M. Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model. Human molecular genetics. 2018;28(3):487-500.
- 7. Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington's disease. Lancet Neurol. 2015;14(11):1135-42.
- 8. Gregory S, Long JD, Kloppel S, Razi A, Scheller E, Minkova L, et al. Testing a longitudinal compensation model in premanifest Huntington's disease. Brain. 2018;141(7):2156-66.
- 9. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986;321(6066):168-71.
- 10. Schwarcz R, Whetsell WO, Mangano RM. Quinolinic Acid an Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat-Brain. Science. 1983;219(4582):316-8.
- 11. Yang SH, Chan AW. Transgenic Animal Models of Huntington's Disease. Current topics in behavioral neurosciences. 2011;7:61-85.
- 12. Rios C, Santamaria A. Quinolinic Acid Is a Potent Lipid Peroxidant in Rat-Brain Homogenates. Neurochem Res. 1991;16(10):1139-43.
- 13. Ishii T, Iwahashi H, Sugata R, Kido R. Formation of Hydroxanthommatin-Derived Radical in the Oxidation of 3-Hydroxykynurenine. Arch Biochem Biophys. 1992;294(2):616-22.
- 14. Hiraku Y, Inoue S, Oikawa S, Yamamoto K, Tada S, Nishino K, et al. Metal-Mediated Oxidative Damage to Cellular and Isolated DNA by Certain Tryptophan-Metabolites. Carcinogenesis. 1995;16(2):349-56.
- 15. Colin-Gonzalez AL, Maldonado PD, Santamaria A. 3-Hydroxykynurenine: An intriguing molecule exerting dual actions in the Central Nervous System. Neurotoxicology. 2013;34:189-204.
- 16. Vecsei L, Beal MF. Intracerebroventricular Injection of Kynurenic Acid, but Not Kynurenine, Induces Ataxia and Stereotyped Behavior in Rats. Brain Res Bull. 1990;25(4):623-7.
- 17. Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic Acid Blocks Neurotoxicity and Seizures Induced in Rats by the Related Brain Metabolite Quinolinic Acid. Neuroscience Letters. 1984;48(3):273-8.

- 18. Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci. 2001;13(11):2141-7.
- 19. Goda K, Hamane Y, Kishimoto R, Ogishi Y. Radical scavenging properties of tryptophan metabolites Estimation of their radical reactivity. Adv Exp Med Biol. 1999;467:397-402.
- 20. Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis. 2006;23(1):190-7.
- 21. Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J Neurol Sci. 1992;108(1):80-7.
- 22. Sathyasaikumar KV, Breda C, Schwarcz R, Giorgini F. Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase. Huntington's Disease. 2018;1780:397-413.
- 23. Sathyasaikumar KV, Stachowski EK, Amori L, Guidetti P, Muchowski PJ, Schwarcz R. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem. 2010;113(6):1416-25.
- 24. Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, et al. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Exp Neurol. 2016;282:99-118.
- 25. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145(6):863-74.
- 26. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet. 2005;37(5):526-31.
- 27. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Current biology: CB. 2011;21(11):961-6.
- 28. Breda C, Sathyasaikumar KV, Idrissi SS, Notarangelo FM, Estranero JG, Moore GGL, et al. Tryptophan-2,3-Dioxygenase (Tdo) Inhibition Ameliorates Neurodegeneration by Modulation of Kynurenine Pathway Metabolites. J Neurol Neurosur Ps. 2016;87:A96-A.
- 29. Green EW, Campesan S, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, et al. Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly. 2012;6(2):117-20.
- 30. Zhang SW, Sakuma M, Deora GS, Levy CW, Klausing A, Breda C, et al. A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Commun Biol. 2019;2.
- 31. Byrne LM, Rodrigues FB, Blennow K, The Track-HD investigators, Durr A, Leavitt BR, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology. 2017;16(8):601-9.
- 32. Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC, et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. Sci Transl Med. 2018;10(458):eaat7108.
- 33. Byrne LM, Wild EJ. Cerebrospinal Fluid Biomarkers for Huntington's Disease. J Huntingtons Dis. 2016;5(1):1-13.

- 34. Schwarcz R, Tamminga CA, Kurlan R, Shoulson I. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. Ann Neurol. 1988;24(4):580-2.
- 35. Heyes MP, Swartz KJ, Markey SP, Beal MF. Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease. Neurosci Lett. 1991;122(2):265-9.
- 36. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992;115 (Pt 5)(5):1249-73.
- 37. Rodrigues FB, Byrne LM, Wild EJ. Biofluid Biomarkers in Huntington's Disease. Methods Mol Biol. 2018;1780:329-96.
- 38. Rodrigues FB, Byrne LM, Tortelli R, Johnson EB, Wijeratne PA, Arridge M, et al. Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington's disease: the prospective HD-CSF study. medRxiv. 2020:2020.03.31.20045260.
- 39. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637-49.
- 40. Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, Gonçalves N, Anderson KE, Cardoso F, et al. Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease. Mov Disord Clin Pract. 2017;4(2):212-24.
- 41. Trundell D, Palermo G, Schobel S, Long JD, Leavitt BR, Tabrizi SJ. Validity, reliability, ability to detect change and meaningful within-patient change of the cUHDRS. J Neurol Neurosurg Psychiatry. 2018;89:A48.
- 42. Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89(24):2495-502.
- 43. Penney JB, Jr., Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41(5):689-92.
- 44. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17(1):87-97.
- 45. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed. 1997;53(1):15-25.
- 46. Whitwell JL, Crum WR, Watt HC, Fox NC. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol. 2001;22(8):1483-9.
- 47. Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol. 2003;60(7):989-94.
- 48. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 2000;11(6 Pt 1):805-21.
- 49. Ledig C, Heckemann RA, Hammers A, Lopez JC, Newcombe VF, Makropoulos A, et al. Robust whole-brain segmentation: application to traumatic brain injury. Med Image Anal. 2015;21(1):40-58.
- 50. Johnson EB, Gregory S, Johnson HJ, Durr A, Leavitt BR, Roos RA, et al. Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease. Frontiers in Neurology. 2017;8(519).

- 51. Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, et al. Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. Sci Rep. 2018;8(1):4260.
- 52. Jacobs KR, Lim CK, Blennow K, Zetterberg H, Chatterjee P, Martins RN, et al. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau. Neurobiol Aging. 2019;80:11-20.
- 53. Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T, et al. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology. 2020;45(6):998-1007.

Supplementary material

Supplementary tables

Table S1 Cohort characteristics. CAG, CAG repeat count; DBS, Disease Burden Score; cUHDRS, composite Unified Huntington's Disease Rating Scale; N/A, not applicable; SD, standard deviation; SDMT, Symbol Digit Modalities Test; SCN, Stroop Color Naming; SWR, Stroop Word Reading; TFC, UHDRS Total Functional Capacity; TMS, UHDRS Total Motor Score; VFC, Verbal Fluency – Categorical.

	All	Participant	S	Healt	thy Contro	ls	Prei	manifest H	D	Manifest HD		
	n	Mean	SD	n	Mean	SD	n	Mean	SD	n	Mean	SD
Demographic												
Gender	80	F38/M42		20	F10/M10		20	F10/M10		40	F18/M22	
Age (years)	80	51.27	11.55	20	50.68	11.03	20	42.38	11.04	40	56.02	9.36
Clinical scores												
CAG	60	42.50	2.03	N/A	N/A	N/A	20	42.00	1.62	40	42.75	2.18
DBS	60	352.80	104.30	N/A	N/A	N/A	20	267.20	61.92	40	395.60	94.64
cUHDRS	79	14.12	4.509	20	17.40	1.49	20	17.98	1.10	39	10.46	3.57
TFC	80	11.20	2.62	20	13.00	0.00	20	13.00	0.00	40	9.40	2.70
TMS	80	20.05	22.34	20	2.35	2.43	20	2.80	2.80	40	37.52	19.43
Cognitive tests												
SDMT	79	40.39	17.28	20	50.90	10.38	20	55.55	9.32	39	27.23	12.60
VFC	80	19.04	6.84	20	24.30	4.12	20	23.30	3.42	40	14.28	5.83
SCN	80	62.10	22.01	20	75.80	13.07	20	81.30	10.12	40	45.65	16.90
SWR	80	81.08	29.22	20	100.20	17.36	20	105.00	11.75	40	59.55	23.63
Imaging volumes ad	justed	for total int	racranial v	olume	(mL)							
Whole brain	64	1121.19	156.02	15	1173.93	115.97	16	1233.56	156.20	33	1042.73	128.99
Caudate volume	63	5.26	1.80	15	6.75	1.38	16	6.29	1.21	32	4.05	1.35
Grey matter	64	648.72	79.49	15	705.93	51.61	16	709.01	46.38	33	593.49	61.39
White matter	64	407.61	41.61	15	439.59	32.64	16	430.41	28.14	33	382.01	34.00

Table S2 Associations between outcomes and disease burden score (DBS), clinical and imaging measures for (A) primary, (B) secondary and (C) exploratory outcomes in gene expansion carriers. 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid; CSF, cerebrospinal fluid; cUHDRS, composite Unified Huntington's Disease Rating Scale; KYN, kynurenine; KYNA, kynurenic acid; r, Pearson's partial correlation coefficient; QUIN, quinolinic acid; SCN, Stroop Color Naming; SDMT, Symbol Digit Modalities Test; SWR, Stroop Word Reading; TFC, UHDRS Total Functional Capacity; TMS, UHDRS Total Motor Score; TRP, tryptophan; VFC, Verbal Fluency – Categorical.

A	Age-a	djusted				Age a	ınd CAG-	adiusted		
	n	r	95% confid	ence interval	p-value	n	r	•	ence interval	p-value
CSF KYNA					Ι					Ι
DBS	60	0.14	-0.12	0.38	0.265	60	0.01	-0.26	0.34	0.961
cUHDRS	59	-0.07	-0.34	0.19	0.616	59	0.03	-0.24	0.27	0.829
TFC	60	-0.12	-0.36	0.13	0.337	60	-0.06	-0.31	0.20	0.666
TMS	60	0.07	-0.18	0.31	0.564	60	-0.02	-0.25	0.22	0.862
SDMT	59	-0.01	-0.27	0.24	0.967	59	0.10	-0.15	0.33	0.432
VFC	60	-0.03	-0.26	0.20	0.833	60	0.08	-0.15	0.30	0.509
SCN	60	-0.09	-0.36	0.19	0.530	60	0.00	-0.28	0.24	0.988
SWR	60	-0.10	-0.37	0.14	0.430	60	-0.02	-0.30	0.22	0.900
Whole brain	49	0.08	-0.17	0.31	0.533	49	0.14	-0.06	0.35	0.191
Caudate volume	48	0.08	-0.16	0.31	0.503	48	0.16	-0.06	0.38	0.150
Grey matter	49	0.09	-0.14	0.32	0.447	49	0.14	-0.08	0.36	0.205
White matter	49	-0.04	-0.34	0.23	0.794	49	-0.01	-0.30	0.23	0.955
CSF 3-HK		I .								
DBS	60	-0.28	-0.51	0.01	0.033	60	-0.11	-0.45	0.16	0.476
cUHDRS	59	0.02	-0.23	0.28	0.857	59	-0.19	-0.40	0.04	0.093
TFC	60	0.05	-0.18	0.31	0.664	60	-0.10	-0.36	0.13	0.418
TMS	60	-0.02	-0.24	0.21	0.851	60	0.17	-0.04	0.37	0.105
SDMT	59	-0.03	-0.27	0.24	0.834	59	-0.23	-0.42	-0.01	0.031
VFC	60	0.13	-0.12	0.36	0.284	60	-0.03	-0.27	0.20	0.814
SCN	60	-0.05	-0.31	0.21	0.692	60	-0.27	-0.45	-0.05	0.009
SWR	60	0.07	-0.18	0.35	0.607	60	-0.12	-0.35	0.11	0.301
Whole brain	49	0.02	-0.27	0.29	0.910	49	-0.12	-0.36	0.10	0.295
Caudate volume	48	0.07	-0.20	0.35	0.618	48	-0.14	-0.34	0.11	0.238
Grey matter	49	-0.05	-0.31	0.22	0.728	49	-0.17	-0.40	0.03	0.114
White matter	49	0.10	-0.16	0.35	0.441	49	0.03	-0.21	0.25	0.779
CSF QUIN		I.	II.		II.			II.	1	1.
DBS	60	-0.02	-0.29	0.24	0.858	60	-0.16	-0.43	0.08	0.206
cUHDRS	59	-0.03	-0.31	0.25	0.832	59	-0.02	-0.32	0.23	0.865
TFC	60	0.04	-0.27	0.32	0.801	60	0.06	-0.27	0.33	0.690
TMS	60	0.01	-0.23	0.24	0.949	60	-0.01	-0.24	0.20	0.947
SDMT	59	-0.14	-0.41	0.12	0.299	59	-0.16	-0.40	0.09	0.202
VFC	60	-0.03	-0.28	0.24	0.822	60	-0.02	-0.27	0.22	0.881
SCN	60	-0.11	-0.38	0.15	0.425	60	-0.12	-0.37	0.12	0.344
SWR	60	0.00	-0.30	0.27	0.992	60	0.02	-0.28	0.29	0.889
Whole brain	49	-0.04	-0.36	0.22	0.773	49	-0.07	-0.37	0.18	0.595
Caudate volume	48	0.15	-0.12	0.38	0.245	48	0.11	-0.14	0.32	0.341
Grey matter	49	-0.01	-0.30	0.26	0.965	49	-0.03	-0.33	0.23	0.829
White matter	49	0.01	-0.29	0.27	0.938	49	0.00	-0.31	0.26	0.974

В

		1 00 0	djusted			Age and CAG-adjusted					
i			_	050/ 22754		a volvo		1	•	intom::01	
- 04	OE 2 HIZ IZVNIA	n	r	95% confide	ence interval	p-value	n	r	95% confide	ence interval	p-value
C	SF 3-HK:KYNA DBS	60	-0.19	-0.45	0.11	0.190	60	0.20	0.42	0.05	0.100
		60					60	-0.20	-0.42	0.05	0.100
	cUHDRS	59	0.04	-0.25	0.28	0.766	59	-0.07	-0.29	0.13	0.519
	TFC	60	-0.01	-0.24	0.25	0.957	60	-0.09	-0.32	0.14	0.416
	TMS	60	-0.02	-0.24	0.28	0.891	60	0.08	-0.14	0.29	0.444
	SDMT	59	0.04	-0.19	0.26	0.714	59	-0.05	-0.25	0.18	0.621
	VFC	60	0.14	-0.13	0.38	0.270	60	0.07	-0.17	0.28	0.518
	SCN	60	-0.04	-0.31	0.19	0.770	60	-0.15	-0.38	0.06	0.176
	SWR	60	0.03	-0.26	0.26	0.790	60	-0.07	-0.32	0.11	0.531
	Whole brain	49	0.18	-0.07	0.42	0.136	49	0.11	-0.11	0.30	0.321
	Caudate volume	48	0.22	0.01	0.42	0.036	48	0.09	-0.11	0.26	0.369
	Grey matter	49	0.09	-0.12	0.32	0.431	49	0.01	-0.20	0.19	0.884
	White matter	49	0.16	-0.15	0.42	0.266	49	0.12	-0.21	0.37	0.423
CS	SF KYNA:KYN										
	DBS	60	0.24	0.01	0.46	0.039	60	0.06	-0.25	0.31	0.692
	cUHDRS	59	-0.22	-0.45	0.04	0.079	59	-0.10	-0.34	0.15	0.425
	TFC	60	-0.27	-0.47	-0.03	0.016	60	-0.18	-0.39	0.05	0.107
	TMS	60	0.22	-0.05	0.43	0.077	60	0.09	-0.12	0.33	0.407
	SDMT	59	-0.18	-0.41	0.06	0.127	59	-0.06	-0.30	0.19	0.654
	VFC	60	-0.25	-0.46	0.01	0.038	60	-0.14	-0.36	0.11	0.243
	SCN	60	-0.24	-0.48	0.04	0.066	60	-0.13	-0.41	0.14	0.379
	SWR	60	-0.22	-0.47	0.03	0.093	60	-0.10	-0.38	0.14	0.472
	Whole brain	49	-0.12	-0.39	0.15	0.382	49	-0.06	-0.27	0.20	0.637
	Caudate volume	48	0.06	-0.18	0.27	0.584	48	0.18	-0.11	0.40	0.173
	Grey matter	49	-0.06	-0.29	0.20	0.628	49	0.00	-0.20	0.17	0.992
	White matter	49	-0.20	-0.47	0.08	0.158	49	-0.16	-0.42	0.11	0.234
CS	SF 3-HK:KYN	1								I.	
	DBS	60	-0.41	-0.61	-0.16	< 0.001	60	-0.23	-0.45	0.02	0.058
	cUHDRS	59	0.19	-0.08	0.42	0.139	59	-0.05	-0.30	0.22	0.728
	TFC	60	0.18	-0.07	0.39	0.127	60	-0.02	-0.27	0.20	0.897
	TMS	60	-0.17	-0.39	0.13	0.180	60	0.06	-0.19	0.31	0.637
	SDMT	59	0.20	-0.05	0.41	0.093	59	-0.01	-0.26	0.30	0.931
	VFC	60	0.38	0.13	0.57	0.001	60	0.21	-0.03	0.43	0.072
	SCN	60	0.12	-0.15	0.34	0.330	60	-0.13	-0.38	0.09	0.272
	SWR	60	0.20	-0.08	0.42	0.115	60	-0.03	-0.27	0.21	0.777
	Whole brain	49	0.24	-0.10	0.48	0.094	49	0.11	-0.13	0.37	0.393
	Caudate volume	48	0.13	-0.11	0.37	0.289	48	-0.12	-0.31	0.09	0.254
	Grey matter	49	0.07	-0.23	0.35	0.629	49	-0.06	-0.26	0.20	0.575
	White matter	49	0.31	-0.02	0.55	0.031	49	0.25	-0.05	0.54	0.096

 \mathbf{C}

C	Age-a	adjusted				Age and CAG-adjusted				
	n	r	95% confide	ence interval	p-value	n	r	95% confid	ence interval	p-value
CSF TRP			L							
DBS	60	-0.10	-0.35	0.14	0.428	60	-0.13	-0.37	0.05	0.203
cUHDRS	59	0.19	-0.09	0.45	0.167	59	0.21	-0.06	0.43	0.104
TFC	60	0.27	0.05	0.47	0.010	60	0.28	0.07	0.47	0.006
TMS	60	-0.20	-0.47	0.08	0.143	60	-0.21	-0.45	0.08	0.106
SDMT	59	0.18	-0.14	0.45	0.234	59	0.18	-0.11	0.43	0.189
VFC	60	0.29	0.06	0.46	0.004	60	0.32	0.10	0.47	0.001
SCN	60	0.07	-0.22	0.29	0.595	60	0.04	-0.23	0.27	0.766
SWR	60	0.11	-0.15	0.31	0.376	60	0.09	-0.17	0.28	0.439
Whole brain	49	0.14	-0.21	0.41	0.384	49	0.10	-0.23	0.40	0.520
Caudate volume	48	0.13	-0.20	0.41	0.409	48	0.08	-0.25	0.38	0.630
Grey matter	49	0.18	-0.16	0.52	0.295	49	0.16	-0.21	0.48	0.389
White matter	49	0.07	-0.19	0.30	0.593	49	0.05	-0.21	0.29	0.716
CSF KYN			I	1	'			I.	11	
DBS	60	0.05	-0.19	0.28	0.669	60	0.02	-0.27	0.25	0.878
cUHDRS	59	-0.14	-0.37	0.12	0.264	59	-0.15	-0.36	0.09	0.217
TFC	60	-0.12	-0.37	0.15	0.360	60	-0.11	-0.37	0.17	0.411
TMS	60	0.13	-0.11	0.35	0.260	60	0.13	-0.11	0.32	0.247
SDMT	59	-0.19	-0.42	0.09	0.162	59	-0.20	-0.41	0.04	0.098
VFC	60	-0.23	-0.41	-0.01	0.027	60	-0.25	-0.43	-0.03	0.017
SCN	60	-0.13	-0.37	0.07	0.270	60	-0.12	-0.34	0.05	0.230
SWR	60	-0.08	-0.32	0.15	0.530	60	-0.06	-0.29	0.15	0.600
Whole brain	49	-0.22	-0.48	0.02	0.079	49	-0.24	-0.48	0.00	0.046
Caudate volume	48	-0.04	-0.28	0.20	0.763	48	-0.05	-0.26	0.18	0.663
Grey matter	49	-0.18	-0.43	0.07	0.183	49	-0.19	-0.45	0.08	0.158
White matter	49	-0.15	-0.39	0.09	0.209	49	-0.16	-0.38	0.08	0.174
CSF AA										
DBS	60	-0.17	-0.38	0.09	0.158	60	-0.16	-0.38	0.12	0.211
cUHDRS	59	0.12	-0.15	0.38	0.395	59	0.04	-0.22	0.31	0.768
TFC	60	0.05	-0.24	0.35	0.742	60	-0.02	-0.34	0.25	0.896
TMS	60	-0.07	-0.34	0.18	0.596	60	0.01	-0.24	0.25	0.957
SDMT	59	0.14	-0.08	0.39	0.238	59	0.08	-0.14	0.32	0.508
VFC	60	0.20	-0.03	0.42	0.088	60	0.15	-0.06	0.35	0.140
SCN	60	0.10	-0.15	0.37	0.469	60	0.03	-0.22	0.27	0.846
SWR	60	0.08	-0.19	0.34	0.543	60	0.00	-0.24	0.28	0.981
Whole brain	49	0.16	-0.10	0.41	0.221	49	0.10	-0.14	0.35	0.426
Caudate volume	48	0.05	-0.22	0.29	0.722	48	-0.07	-0.27	0.16	0.531
Grey matter	49	0.13	-0.13	0.43	0.384	49	0.07	-0.19	0.35	0.598
White matter	49	0.10	-0.15	0.35	0.448	49	0.06	-0.19	0.29	0.623

	Age-a	adjusted				Age and CAG-adjusted				
	n	r	95% confid	ence interval	p-value	n	r	95% confid	ence interval	p-value
Plasma TRP			1		II.			I .		Ш
DBS	58	-0.27	-0.45	-0.08	0.003	58	-0.09	-0.29	0.15	0.421
cUHDRS	57	0.23	-0.04	0.45	0.064	57	0.10	-0.21	0.34	0.461
TFC	58	0.19	-0.07	0.38	0.102	58	0.05	-0.20	0.27	0.665
TMS	58	-0.30	-0.54	-0.03	0.022	58	-0.18	-0.45	0.14	0.221
SDMT	57	0.24	-0.04	0.45	0.053	57	0.12	-0.12	0.34	0.307
VFC	58	0.30	0.01	0.46	0.005	58	0.19	-0.14	0.36	0.102
SCN	58	0.17	-0.13	0.39	0.197	58	0.02	-0.31	0.26	0.897
SWR	58	0.20	-0.08	0.41	0.087	58	0.06	-0.24	0.28	0.642
Whole brain	47	0.20	-0.06	0.47	0.140	47	0.12	-0.21	0.38	0.419
Caudate volume	46	0.10	-0.28	0.42	0.580	46	-0.04	-0.46	0.30	0.836
Grey matter	47	0.19	-0.06	0.44	0.146	47	0.12	-0.20	0.36	0.409
White matter	47	0.16	-0.07	0.39	0.159	47	0.12	-0.14	0.33	0.305
Plasma KYN			1	1		J.		II.	1	1
DBS	58	0.02	-0.26	0.33	0.909	58	0.06	-0.24	0.37	0.722
cUHDRS	57	0.06	-0.22	0.34	0.700	57	0.07	-0.16	0.32	0.566
TFC	58	-0.04	-0.33	0.28	0.817	58	-0.04	-0.33	0.26	0.764
TMS	58	-0.08	-0.36	0.20	0.585	58	-0.10	-0.34	0.13	0.408
SDMT	57	0.12	-0.13	0.39	0.365	57	0.15	-0.10	0.37	0.207
VFC	58	0.05	-0.20	0.29	0.670	58	0.07	-0.14	0.26	0.508
SCN	58	0.01	-0.25	0.23	0.961	58	0.01	-0.21	0.22	0.934
SWR	58	-0.03	-0.26	0.20	0.776	58	-0.04	-0.22	0.15	0.655
Whole brain	47	0.04	-0.31	0.36	0.814	47	0.03	-0.25	0.32	0.820
Caudate volume	46	-0.02	-0.32	0.26	0.913	46	-0.03	-0.31	0.20	0.811
Grey matter	47	0.08	-0.22	0.43	0.630	47	0.08	-0.19	0.41	0.620
White matter	47	-0.01	-0.32	0.22	0.921	47	-0.02	-0.30	0.23	0.890
Plasma KYNA				1		ı.			1	
DBS	51	-0.03	-0.29	0.24	0.830	51	-0.04	-0.31	0.35	0.826
cUHDRS	50	0.27	0.00	0.53	0.050	50	0.37	0.12	0.54	< 0.001
TFC	51	0.28	-0.01	0.54	0.040	51	0.34	0.03	0.56	0.009
TMS	51	-0.31	-0.53	-0.01	0.022	51	-0.38	-0.55	-0.13	< 0.001
SDMT	50	0.29	0.02	0.56	0.037	50	0.37	0.18	0.56	< 0.001
VFC	51	0.21	-0.04	0.44	0.096	51	0.24	0.01	0.42	0.019
SCN	51	0.14	-0.12	0.42	0.306	51	0.16	-0.08	0.36	0.157
SWR	51	0.21	-0.06	0.45	0.108	51	0.26	0.04	0.45	0.010
Whole brain	40	0.10	-0.26	0.37	0.522	40	0.09	-0.26	0.36	0.544
Caudate volume	39	0.20	-0.11	0.46	0.172	39	0.21	-0.04	0.43	0.094
Grey matter	40	0.12	-0.22	0.44	0.475	40	0.12	-0.22	0.40	0.458
White matter	40	0.02	-0.27	0.27	0.910	40	0.01	-0.30	0.25	0.947

	Age-a	adjusted				Age and CAG-adjusted				
	n	r	95% confid	ence interval	p-value	n	r	95% confid	ence interval	p-value
Plasma 3-HK			I.		•			I.		1
DBS	58	0.19	-0.07	0.41	0.124	58	0.04	-0.21	0.24	0.753
cUHDRS	57	-0.01	-0.28	0.28	0.971	57	0.15	-0.09	0.40	0.242
TFC	58	-0.04	-0.33	0.27	0.799	58	0.08	-0.22	0.37	0.575
TMS	58	0.02	-0.25	0.28	0.887	58	-0.13	-0.36	0.10	0.272
SDMT	57	0.01	-0.30	0.30	0.958	57	0.14	-0.12	0.41	0.285
VFC	58	-0.03	-0.26	0.23	0.830	58	0.11	-0.09	0.31	0.267
SCN	58	-0.06	-0.31	0.23	0.655	58	0.07	-0.16	0.29	0.565
SWR	58	-0.09	-0.31	0.18	0.494	58	0.04	-0.16	0.25	0.682
Whole brain	47	0.00	-0.31	0.29	0.975	47	0.05	-0.21	0.35	0.723
Caudate volume	46	0.03	-0.30	0.29	0.844	46	0.11	-0.17	0.41	0.459
Grey matter	47	0.02	-0.27	0.30	0.875	47	0.06	-0.22	0.37	0.662
White matter	47	-0.08	-0.35	0.21	0.592	47	-0.05	-0.33	0.20	0.684
Plasma AA			1	1				1	1	
DBS	53	0.11	-0.20	0.36	0.428	53	0.06	-0.18	0.29	0.610
cUHDRS	52	-0.12	-0.36	0.13	0.337	52	-0.05	-0.27	0.18	0.670
TFC	53	-0.05	-0.32	0.26	0.750	53	0.01	-0.24	0.32	0.963
TMS	53	-0.05	-0.35	0.22	0.738	53	-0.13	-0.40	0.10	0.318
SDMT	52	-0.11	-0.35	0.14	0.389	52	-0.04	-0.28	0.18	0.722
VFC	53	-0.12	-0.39	0.17	0.404	53	-0.08	-0.32	0.17	0.556
SCN	53	-0.08	-0.32	0.20	0.553	53	-0.02	-0.26	0.24	0.844
SWR	53	-0.08	-0.33	0.22	0.577	53	-0.02	-0.26	0.23	0.845
Whole brain	44	-0.07	-0.34	0.22	0.653	44	0.01	-0.26	0.22	0.957
Caudate volume	43	0.03	-0.21	0.26	0.830	43	0.16	-0.07	0.37	0.163
Grey matter	44	0.00	-0.29	0.28	0.993	44	0.06	-0.20	0.29	0.619
White matter	44	-0.18	-0.45	0.07	0.185	44	-0.15	-0.40	0.09	0.250
Plama QUIN			1	1				1	1	1
DBS	57	-0.02	-0.26	0.28	0.897	57	0.09	-0.13	0.35	0.463
cUHDRS	56	0.11	-0.20	0.38	0.450	56	0.11	-0.17	0.40	0.454
TFC	57	0.02	-0.28	0.31	0.873	57	0.00	-0.29	0.27	0.995
TMS	57	-0.10	-0.33	0.15	0.427	57	-0.09	-0.31	0.15	0.464
SDMT	56	0.22	-0.05	0.46	0.096	56	0.24	-0.06	0.49	0.087
VFC	57	0.09	-0.18	0.31	0.470	57	0.08	-0.15	0.32	0.506
SCN	57	0.09	-0.17	0.40	0.552	57	0.07	-0.20	0.41	0.639
SWR	57	0.07	-0.21	0.39	0.665	57	0.05	-0.25	0.37	0.766
Whole brain	47	-0.03	-0.33	0.29	0.865	47	-0.03	-0.29	0.28	0.810
Caudate volume	46	-0.01	-0.25	0.27	0.963	46	-0.02	-0.23	0.21	0.891
Grey matter	47	0.05	-0.24	0.37	0.742	47	0.05	-0.23	0.34	0.753
White matter	47	-0.12	-0.38	0.25	0.441	47	-0.13	-0.39	0.23	0.415

Table S3 Within-subject short-term stability for primary, secondary and exploratory outcomes. 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid; CSF, cerebrospinal fluid; ICC, KYN, kynurenine; KYNA, kynurenic acid; QUIN, quinolinic acid; TRP, tryptophan.

	ICC	95% confidence interval				
Primary Outcomes						
CSF KYNA	0.84	0.58	0.94			
CSF 3-HK	0.68	0.27	0.88			
CSF QUIN	0.90	0.72	0.96			
Secondary Outcomes	1		1			
CSF 3-HK:KYNA	0.78	0.46	0.92			
CSF KYNA:KYN	0.43	-0.09	0.76			
CSF 3-HK:KYN	0.78	0.47	0.92			
Exploratory Outcome	S					
CSF TRP	0.58	0.11	0.83			
CSF KYN	0.67	0.25	0.87			
CSF AA	0.84	0.58	0.94			
Plasma TRP	0.58	0.09	0.84			
Plasma KYN	0.54	0.03	0.82			
Plasma KYNA	-0.16	-0.68	0.45			
Plasma 3-HK	0.57	0.08	0.84			
Plasma AA	0.80	0.41	0.94			
Plasma QUIN	0.89	0.69	0.96			

Table S4 Associations and ratios between CSF and plasma. 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid, KYN, kynurenine; KYNA, kynurenic acid; QUIN, quinolinic acid; r, Pearson's partial correlation coefficient; TRP, tryptophan.

		n	r	95% confiden	ce interval	p-value	CSF to plasma ratio
TR	P	78	0.43	0.21	0.60	< 0.001	0.04
KY	'N	78	-0.55	-0.70	-0.36	< 0.001	23.43
KY	'NA	70	0.17	-0.13	0.43	0.229	0.06
3-H	łK	77	-0.42	-0.57	-0.22	< 0.001	0.11
AA	ν.	71	-0.48	-0.63	-0.29	< 0.001	0.31
QU	JIN	77	-0.75	-0.83	-0.66	< 0.001	0.06

Supplementary figures




Figure S1 Distributions and arithmetic operations used to transform primary outcomes: cerebrospinal fluid (CSF) kynurenic acid (KYNA), CSF 3-hydroxykynurenine (3-HK) and CSF quinolinic acid (QUIN). Top row depicts a quantile-quantile plot for observed distribution against normal distribution, middle row shows a quantile-quantile plot for transformed distribution against normal distribution, and the bottom row a histogram for transformed distribution.




Figure S2 Distributions and arithmetic operations used to transform secondary outcomes: ratios of cerebrospinal fluid (CSF) 3-hydroxykynurenine to kynurenic acid (3-HK:KYNA), CSF kynurenic acid to kynurenine (KYNA:KYN) and CSF 3-hydroxykynurenine to kynurenine (3-HK:KYN). Top row depicts a quantile-quantile plot for observed distribution against normal distribution, middle row shows a quantile-quantile plot for transformed distribution against normal distribution, and the bottom row a histogram for transformed distribution.




Figure S3 Distributions and arithmetic operations used to transform exploratory outcomes: cerebrospinal fluid (CSF) tryptophan (TRP), CSF kynurenine (KYN), CSF anthranilic acid (AA), plasma TRP, plasma KYN, plasma KYNA, plasma 3-hydroxykynurenine (3-HK), plasma AA, and plasma quinolinic acid (QUIN). In each of the three 3 by 3 subpanels, top row depicts a quantile-quantile plot for observed distribution against normal distribution, middle row shows a quantile-quantile plot for transformed distribution against normal distribution, and the bottom row a histogram for transformed distribution.




Figure S4 Associations between age (healthy controls only, top row), gender (second row), CAG repeat count (gene expansion carriers only, middle row), CSF haemoglobin (third row) and time in the freezer (bottom row) and primary outcomes: cerebrospinal fluid (CSF) kynurenic acid (KYNA), CSF 3-hydroxykynurenine (3-HK) and CSF quinolinic acid (QUIN). Grey represents healthy controls, light orange preHD and dark orange HD.




Figure S5 Associations between age (healthy controls only, top row), gender (second row), CAG repeat count (gene expansion carriers only, middle row), CSF haemoglobin (third row) and time in the freezer (bottom row) and secondary outcomes: ratios of cerebrospinal fluid (CSF) 3-hydroxykynurenine to kynurenic acid (3-HK:KYNA), CSF kynurenic acid to kynurenine (KYNA:KYN) and CSF 3-hydroxykynurenine to kynurenine (3-HK:KYN). Grey represents healthy controls, light orange preHD and dark orange HD.




Figure S6 Associations between age (healthy controls only, top row), gender (second row), CAG repeat count (gene expansion carriers only, middle row), CSF haemoglobin (third row) and time in the freezer (bottom row) and exploratory outcomes: cerebrospinal fluid (CSF) tryptophan (TRP), CSF kynurenine (KYN), CSF anthranilic acid (AA), plasma TRP, plasma KYN, plasma KYNA, plasma 3-hydroxykynurenine (3-HK), plasma AA, and plasma quinolinic acid (QUIN). Grey represents healthy controls, light orange preHD and dark orange HD.









Figure S7 Intergroup differences (top row), associations with Disease Burden Score (DBS, second row) and composite Unified Huntington's Disease Rating Scale (cUHDRS, third row), and within-subject short-term stability (bottom row) for exploratory outcomes: cerebrospinal fluid (CSF) tryptophan (TRP), CSF kynurenine (KYN), CSF anthranilic acid (AA), plasma TRP, plasma KYN, plasma KYNA, plasma 3-hydroxykynurenine (3-HK), plasma AA, and plasma quinolinic acid (QUIN). Grey represents healthy controls, light orange preHD and dark orange HD.

















Figure S8 Associations between primary, secondary and exploratory outcomes and clinical and imaging measures. Grey represents healthy controls, light orange preHD and dark orange

HD. 3-HK, 3-hydroxykynurenine; AA, Anthranilic acid; CSF, cerebrospinal fluid; cUHDRS, composite Unified Huntington's Disease Rating Scale; KYN, kynurenine; KYNA, kynurenic acid; r, Pearson's partial correlation coefficient; QUIN, quinolinic acid; SCN, Stroop Color Naming; SDMT, Symbol Digit Modalities Test; SWR, Stroop Word Reading; TFC, UHDRS Total Functional Capacity; TMS, UHDRS Total Motor Score; TRP, tryptophan; VFC, Verbal Fluency – Categorical.

